Loading
A phase 1/2 trial of pembrolizumab in colorectal cancer, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), now recruiting.
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study is a phase 1/2, interventional study registered as NCT04014530 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), with a registry enrolment figure of 47 participants, started 2019-08-01 and due to reach its primary completion in 2023-06-01. Interventions recorded: Ataluren + Pembrolizumab. Conditions listed: Colorectal Cancer; Endometrium Cancer. Primary outcome: Incidence of treatment-Emergent Adverse Event and the determination of the maximum tolerable dose of Ataluren.; Objective response rate. Colorectal eligibility wording from the registry: "inaccessible by colonoscopy or CT-guided approaches or due to safety concerns) may submit an archived specimen only upon agreement from the Sponsor". Sites: Netherlands. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/